Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Diabetes

  Free Subscription


Articles published in Lancet

Retrieve available abstracts of 87 articles:
HTML format
Text format



Single Articles


    October 2019
  1. BERGENSTAL RM, Johnson ML, Bashan E, Hodish I, et al
    Insulin dosing guidance to optimise type 2 diabetes management - Authors' reply.
    Lancet. 2019;394:1321.
    PubMed     Text format    


  2. GARG R
    Insulin dosing guidance to optimise type 2 diabetes management.
    Lancet. 2019;394:1320-1321.
    PubMed     Text format    


    September 2019
  3. MOSENZON O, Leibowitz G
    VERIFY the role of initial combination therapy in patients with type 2 diabetes.
    Lancet. 2019 Sep 17. pii: S0140-6736(19)32165.
    PubMed     Text format    


  4. MATTHEWS DR, Paldanius PM, Proot P, Chiang Y, et al
    Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial.
    Lancet. 2019 Sep 17. pii: S0140-6736(19)32131.
    PubMed     Text format     Abstract available


  5. BECK RW, Bergenstal RM, Laffel LM, Pickup JC, et al
    Advances in technology for management of type 1 diabetes.
    Lancet. 2019 Sep 13. pii: S0140-6736(19)31142.
    PubMed     Text format     Abstract available


  6. DAYAN CM, Korah M, Tatovic D, Bundy BN, et al
    Changing the landscape for type 1 diabetes: the first step to prevention.
    Lancet. 2019 Sep 13. pii: S0140-6736(19)32127.
    PubMed     Text format     Abstract available


  7. VANTYGHEM MC, de Koning EJP, Pattou F, Rickels MR, et al
    Advances in beta-cell replacement therapy for the treatment of type 1 diabetes.
    Lancet. 2019 Sep 13. pii: S0140-6736(19)31334.
    PubMed     Text format     Abstract available


    August 2019
  8. VALGIMIGLI M, Manavifar N
    Ticagrelor in patients with diabetes and previous PCI.
    Lancet. 2019 Aug 30. pii: S0140-6736(19)31957.
    PubMed     Text format    


  9. BHATT DL, Steg PG, Mehta SR, Leiter LA, et al
    Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial.
    Lancet. 2019 Aug 30. pii: S0140-6736(19)31887.
    PubMed     Text format     Abstract available


  10. ROSHANDEL G, Khoshnia M, Poustchi H, Hemming K, et al
    Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial.
    Lancet. 2019;394:672-683.
    PubMed     Text format     Abstract available


  11. ZELNIKER TA, Wiviott SD, Raz I, Sabatine MS, et al
    SGLT-2 inhibitors for people with type 2 diabetes - Authors' reply.
    Lancet. 2019;394:560-561.
    PubMed     Text format    


  12. STRANDBERG TE, Petrovic M, Benetos A
    SGLT-2 inhibitors for people with type 2 diabetes.
    Lancet. 2019;394:560.
    PubMed     Text format    


  13. MALAGA G, Ruiz EF
    SGLT-2 inhibitors for people with type 2 diabetes.
    Lancet. 2019;394:559-560.
    PubMed     Text format    


  14. BARNETT R
    Type 2 diabetes.
    Lancet. 2019;394:557.
    PubMed     Text format    


  15. HOORN EJ
    Testing the waters: a new test for hypotonic polyuria.
    Lancet. 2019;394:546-547.
    PubMed     Text format    


  16. LEVAILLANT M, Lievre G, Baert G
    Ending diabetes in Mexico.
    Lancet. 2019;394:467-468.
    PubMed     Text format    


    July 2019
  17. WINZELER B, Cesana-Nigro N, Refardt J, Vogt DR, et al
    Arginine-stimulated copeptin measurements in the differential diagnosis of diabetes insipidus: a prospective diagnostic study.
    Lancet. 2019 Jul 11. pii: S0140-6736(19)31255.
    PubMed     Text format     Abstract available


  18. HOLST JJ
    Which to choose, an oral or an injectable glucagon-like peptide-1 receptor agonist?
    Lancet. 2019;394:4-6.
    PubMed     Text format    


    June 2019
  19. GERSTEIN HC, Colhoun HM, Dagenais GR, Diaz R, et al
    Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
    Lancet. 2019 Jun 7. pii: S0140-6736(19)31149.
    PubMed     Text format     Abstract available


  20. VERMA S, Mazer CD, Perkovic V
    Is it time to REWIND the cardiorenal clock in diabetes?
    Lancet. 2019 Jun 7. pii: S0140-6736(19)31267.
    PubMed     Text format    


  21. GERSTEIN HC, Colhoun HM, Dagenais GR, Diaz R, et al
    Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.
    Lancet. 2019 Jun 7. pii: S0140-6736(19)31150.
    PubMed     Text format     Abstract available


  22. PRATLEY R, Amod A, Hoff ST, Kadowaki T, et al
    Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
    Lancet. 2019 Jun 7. pii: S0140-6736(19)31271.
    PubMed     Text format     Abstract available


    May 2019
  23. LUO J, Gonsalves G, Greene J
    Insulin for all: treatment activism and the global diabetes crisis.
    Lancet. 2019;393:2116-2117.
    PubMed     Text format    


  24. RABER I, McCarthy CP, Vaduganathan M, Bhatt DL, et al
    The rise and fall of aspirin in the primary prevention of cardiovascular disease.
    Lancet. 2019;393:2155-2167.
    PubMed     Text format     Abstract available


  25. GREGG EW, Cheng Y, Imperatore G
    Trend analysis of diabetic mortality - Authors' reply.
    Lancet. 2019;393:1932.
    PubMed     Text format    


  26. YUAN X, Song F, Zhang L
    Trend analysis of diabetic mortality.
    Lancet. 2019;393:1931-1932.
    PubMed     Text format    


  27. WATTS G
    Shitaye Alemu Balcha: committed to rural health care in Ethiopia.
    Lancet. 2019;393:1797.
    PubMed     Text format    


    April 2019
  28. ZHONG D, Yi Y, Lin C
    A kidney changes size: first increasing and then decreasing.
    Lancet. 2019;393:1641.
    PubMed     Text format    


  29. TUTTLE KR
    A turning point for chronic kidney disease in diabetes.
    Lancet. 2019 Apr 12. pii: S0140-6736(19)30855.
    PubMed     Text format    


  30. HEERSPINK HJL, Parving HH, Andress DL, Bakris G, et al
    Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.
    Lancet. 2019 Apr 12. pii: S0140-6736(19)30772.
    PubMed     Text format     Abstract available


    March 2019
  31. THE LANCET
    Gestational diabetes in England: cause for concern.
    Lancet. 2019;393:1262.
    PubMed     Text format    


  32. EVANS ML, Golubic R
    Technology to overcome clinical inertia in insulin therapy.
    Lancet. 2019;393:1078-1080.
    PubMed     Text format    


  33. COSTACOU T, Guo J, Miller RG, Orchard TJ, et al
    Excess mortality and cardiovascular disease risk in type 1 diabetes.
    Lancet. 2019;393:985.
    PubMed     Text format    


  34. RAWSHANI A, Sattar N, Franzen S, Rawshani A, et al
    Excess mortality and cardiovascular disease risk in type 1 diabetes - Authors' reply.
    Lancet. 2019;393:985-986.
    PubMed     Text format    


  35. SNAITH JR, Holmes-Walker DJ, Girgis CM, Greenfield JR, et al
    Excess mortality and cardiovascular disease risk in type 1 diabetes.
    Lancet. 2019;393:984-985.
    PubMed     Text format    


  36. XIAO F, Liu M, Wang XF
    Involuntary choreiform movements in a diabetic patient.
    Lancet. 2019;393:1033.
    PubMed     Text format    


    February 2019
  37. BERGENSTAL RM, Johnson M, Passi R, Bhargava A, et al
    Automated insulin dosing guidance to optimise insulin management in patients with type 2 diabetes: a multicentre, randomised controlled trial.
    Lancet. 2019 Feb 22. pii: S0140-6736(19)30368.
    PubMed     Text format     Abstract available


    January 2019
  38. STEDMAN M, Lunt M, Livingston M, Fryer AA, et al
    The costs of drug prescriptions for diabetes in the NHS.
    Lancet. 2019;393:226-227.
    PubMed     Text format    


  39. THE LANCET
    Modernising the NHS: leading the way with diabetes.
    Lancet. 2019;393:200.
    PubMed     Text format    


  40. VERMA S, Juni P, Mazer CD
    Pump, pipes, and filter: do SGLT2 inhibitors cover it all?
    Lancet. 2019;393:3-5.
    PubMed     Text format    


    December 2018
  41. SANYAL A, Charles ED, Neuschwander-Tetri BA, Loomba R, et al
    Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial.
    Lancet. 2018 Dec 13. pii: S0140-6736(18)31785.
    PubMed     Text format     Abstract available


  42. THE LANCET
    Type 2 diabetes: the urgent need to protect young people.
    Lancet. 2018;392:2325.
    PubMed     Text format    


    November 2018
  43. UNAMUNO X, Fruhbeck G
    Lorcaserin: balancing efficacy with potential risks.
    Lancet. 2018;392:2239-2240.
    PubMed     Text format    


  44. STUMVOLL M, Tschop M
    Twice the benefits with twincretins?
    Lancet. 2018;392:2142-2144.
    PubMed     Text format    


  45. ZELNIKER TA, Wiviott SD, Raz I, Im K, et al
    SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
    Lancet. 2018 Nov 9. pii: S0140-6736(18)32590.
    PubMed     Text format     Abstract available


    October 2018
  46. TAYLOR R, Adamson AJ, Sattar N, Lean MEJ, et al
    VLCD for weight loss and remission of type 2 diabetes? - Authors' reply.
    Lancet. 2018;392:1307.
    PubMed     Text format    


  47. AHMAD N, Alfaris N
    VLCD for weight loss and remission of type 2 diabetes?
    Lancet. 2018;392:1306-1307.
    PubMed     Text format    


  48. BOHULA EA, Scirica BM, Inzucchi SE, McGuire DK, et al
    Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial.
    Lancet. 2018 Oct 3. pii: S0140-6736(18)32328.
    PubMed     Text format     Abstract available


  49. FRIAS JP, Nauck MA, Van J, Kutner ME, et al
    Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
    Lancet. 2018 Oct 3. pii: S0140-6736(18)32260.
    PubMed     Text format     Abstract available


  50. GALDERISI A, Sherr JL
    Enlarging the loop: closed-loop insulin delivery for type 1 diabetes.
    Lancet. 2018 Oct 1. pii: S0140-6736(18)32329.
    PubMed     Text format    


  51. TAUSCHMANN M, Thabit H, Bally L, Allen JM, et al
    Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial.
    Lancet. 2018 Oct 1. pii: S0140-6736(18)31947.
    PubMed     Text format     Abstract available


  52. HERNANDEZ AF, Green JB, Janmohamed S, D'Agostino RB Sr, et al
    Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.
    Lancet. 2018 Oct 1. pii: S0140-6736(18)32261.
    PubMed     Text format     Abstract available


  53. MAFHAM M, Preiss D
    HARMONY or discord in cardiovascular outcome trials of GLP-1 receptor agonists?
    Lancet. 2018 Oct 1. pii: S0140-6736(18)32348.
    PubMed     Text format    


    September 2018

  54. NCD Countdown 2030: worldwide trends in non-communicable disease mortality and progress towards Sustainable Development Goal target 3.4.
    Lancet. 2018;392:1072-1088.
    PubMed     Text format     Abstract available


    August 2018
  55. KLUGER AY, McCullough PA
    Semaglutide and GLP-1 analogues as weight-loss agents.
    Lancet. 2018;392:615-616.
    PubMed     Text format    


  56. RAWSHANI A, Sattar N, Franzen S, Rawshani A, et al
    Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study.
    Lancet. 2018;392:477-486.
    PubMed     Text format     Abstract available


  57. BASINA M, Maahs DM
    Age at type 1 diabetes onset: a new risk factor and call for focused treatment.
    Lancet. 2018;392:453-454.
    PubMed     Text format    


  58. MCCALL C
    Biosimilars for insulin: a cost-saving alternative?
    Lancet. 2018;392:463-464.
    PubMed     Text format    


    July 2018
  59. PALMER SC, Strippoli GFM
    Metformin as first-line treatment for type 2 diabetes.
    Lancet. 2018;392:120.
    PubMed     Text format    


    June 2018
  60. RAYNER CK, Horowitz M
    Agonism of receptors in the gut-pancreas axis in type 2 diabetes: are two better than one?
    Lancet. 2018 Jun 22. pii: S0140-6736(18)30936.
    PubMed     Text format    


  61. AMBERY P, Parker VE, Stumvoll M, Posch MG, et al
    MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study.
    Lancet. 2018 Jun 22. pii: S0140-6736(18)30726.
    PubMed     Text format     Abstract available


  62. LANGENBERG C, Lotta LA
    Genomic insights into the causes of type 2 diabetes.
    Lancet. 2018;391:2463-2474.
    PubMed     Text format     Abstract available


  63. DIMEGLIO LA, Evans-Molina C, Oram RA
    Type 1 diabetes.
    Lancet. 2018;391:2449-2462.
    PubMed     Text format     Abstract available


  64. PATEL T, Tesfaldet B, Chowdhury I, Kettermann A, et al
    Endpoints in diabetes cardiovascular outcome trials.
    Lancet. 2018;391:2412.
    PubMed     Text format    


  65. STEYN M, Couchman L, Coombes G, Earle KA, et al
    A herbal treatment for type 2 diabetes adulterated with undisclosed drugs.
    Lancet. 2018;391:2411.
    PubMed     Text format    


  66. THE LANCET
    Untangling the complications of diabetes.
    Lancet. 2018;391:2389.
    PubMed     Text format    


    May 2018
  67. BENNETT PH
    Diabetes mortality in the USA: winning the battle but not the war?
    Lancet. 2018 May 18. pii: S0140-6736(18)30843.
    PubMed     Text format    


  68. GREGG EW, Cheng YJ, Srinivasan M, Lin J, et al
    Trends in cause-specific mortality among adults with and without diagnosed diabetes in the USA: an epidemiological analysis of linked national survey and vital statistics data.
    Lancet. 2018 May 18. pii: S0140-6736(18)30314.
    PubMed     Text format     Abstract available


    March 2018
  69. CHATTERJEE S, Khunti K, Davies MJ
    Type 2 diabetes - Authors' reply.
    Lancet. 2018;391:1262.
    PubMed     Text format    


  70. TATE AR
    Type 2 diabetes.
    Lancet. 2018;391:1261-1262.
    PubMed     Text format    


  71. BOUSSAGEON R, Roustit M, Gueyffier F, Tudrej BV, et al
    Type 2 diabetes.
    Lancet. 2018;391:1261.
    PubMed     Text format    


    February 2018
  72. BHATT DL
    CABG the clear choice for patients with diabetes and multivessel disease.
    Lancet. 2018 Feb 22. pii: S0140-6736(18)30424.
    PubMed     Text format    


  73. SARHAN MB, Ghandour R, Rmeileh NMEA
    The effectiveness of counselling interventions in reducing HbA1c concentrations in patients with type 2 diabetes: a modelling study.
    Lancet. 2018;391 Suppl 2:S30.
    PubMed     Text format     Abstract available


  74. SAMAN KA, Massad S, Ibaid AA, Anan H, et al
    Factors associated with depression in patients with type 2 diabetes in the Gaza Strip: a cross sectional study.
    Lancet. 2018;391 Suppl 2:S19.
    PubMed     Text format     Abstract available


  75. CANALI G, Tittle V, Seita A
    Medication adherence by Palestine refugees living in Jordan who have diabetes: a cross-sectional study.
    Lancet. 2018;391 Suppl 2:S13.
    PubMed     Text format     Abstract available


  76. BERGENSTAL RM
    Continuous glucose monitoring: transforming diabetes management step by step.
    Lancet. 2018 Feb 15. pii: S0140-6736(18)30290.
    PubMed     Text format    


  77. HEINEMANN L, Freckmann G, Ehrmann D, Faber-Heinemann G, et al
    Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial.
    Lancet. 2018 Feb 15. pii: S0140-6736(18)30297.
    PubMed     Text format     Abstract available


    January 2018
  78. BARNETT R
    Type 1 diabetes.
    Lancet. 2018;391:195.
    PubMed     Text format    


    December 2017
  79. UUSITUPA M
    Remission of type 2 diabetes: mission not impossible.
    Lancet. 2017 Dec 4. pii: S0140-6736(17)33100.
    PubMed     Text format    


  80. LEAN ME, Leslie WS, Barnes AC, Brosnahan N, et al
    Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial.
    Lancet. 2017 Dec 4. pii: S0140-6736(17)33102.
    PubMed     Text format     Abstract available


    November 2017
  81. BROWN DM, Wykoff CC
    Intravitreal aflibercept for proliferative diabetic retinopathy.
    Lancet. 2017;390:2141.
    PubMed     Text format    


  82. SIVAPRASAD S, Prevost AT, Vasconcelos J, Riddell A, et al
    Intravitreal aflibercept for proliferative diabetic retinopathy - Authors' reply.
    Lancet. 2017;390:2141-2142.
    PubMed     Text format    


  83. LIU L, Tham YC, Cheng CY
    Intravitreal aflibercept for proliferative diabetic retinopathy.
    Lancet. 2017;390:2140-2141.
    PubMed     Text format    


    October 2017
  84. MCGAVOCK J, Wicklow B, Dart AB
    Type 2 diabetes in youth is a disease of poverty.
    Lancet. 2017;390:1829.
    PubMed     Text format    


    September 2017
  85. GARG SK, Polsky S
    Continuous glucose monitoring in pregnant women with type 1 diabetes.
    Lancet. 2017 Sep 14. pii: S0140-6736(17)32449.
    PubMed     Text format    


  86. FEIG DS, Donovan LE, Corcoy R, Murphy KE, et al
    Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial.
    Lancet. 2017 Sep 14. pii: S0140-6736(17)32400.
    PubMed     Text format     Abstract available


  87. JEFFCOATE W, Barron E, Lomas J, Valabhji J, et al
    Using data to tackle the burden of amputation in diabetes.
    Lancet. 2017 Sep 11. pii: S0140-6736(17)32401.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Diabetes is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: